LATESTSEARCH ⌕
NASDAQ / LIVE COMPANY INTELLIGENCE

YD Bio Limited

Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.

TICKERYDES
CORENasdaq-listed company
WATCHEarnings + filings + operating news
STATUSContinuously updated
LIVE / YDES COVERAGE

What’s moving YD Bio Limited now

Current reporting with the operating signal separated from the noise.

01
YD Bio Limited

YD Bio Limited

The story matters when it changes YD Bio Limited’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
02
YD Bio Limited CEO Dr. Ethan Shen Details Strategic Roadmap for Integrated Oncology Ecosystem

YD Bio Limited CEO Dr. Ethan Shen Details Strategic Roadmap for Integrated Oncology Ecosystem

The development tests whether YD Bio Limited can turn product investment into adoption, revenue and durable advantage.

Watch next: confirmation in a company filing, official release or regulator record.
03
YD Bio Limited: YD Bio Expands U.S. Laboratory Footprint to 46 States, Strengthening DNA-Methylation Early Cancer Detection Operations

YD Bio Limited: YD Bio Expands U.S. Laboratory Footprint to 46 States, Strengthening DNA-Methylation Early Cancer Detection Operations

The story matters when it changes YD Bio Limited’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
04
YD Bio Limited Enters into Binding Letter of Intent to Acquire Safe Save Medical Cell Sciences & Technology Co., Ltd., Bolstering Leadership in Advanced Immunocell Therapy

YD Bio Limited Enters into Binding Letter of Intent to Acquire Safe Save Medical Cell Sciences & Technology Co., Ltd., Bolstering Leadership in Advanced Immunocell Therapy

The story matters when it changes YD Bio Limited’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
05
YD Bio Limited Announces U.S. Ophthalmology Market Entry, Advances Across Diagnostics and LSC Exosome Therapeutics

YD Bio Limited Announces U.S. Ophthalmology Market Entry, Advances Across Diagnostics and LSC Exosome Therapeutics

The story matters when it changes YD Bio Limited’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
06
YD Bio Limited Reports Unaudited Half Year 2025 Financial Results

YD Bio Limited Reports Unaudited Half Year 2025 Financial Results

The story matters when it changes YD Bio Limited’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
PRIMARY DOCUMENTS / SEC EDGAR

Latest YDES filings.

Investor-relevant reports are shown first, followed by the company’s other recent official submissions.

6-KOfficial SEC filingFiled 2026-05-01 · Period 2026-04-30SEC ↗20-FOfficial SEC filingFiled 2026-04-30 · Period 2025-12-31SEC ↗4Official SEC filingFiled 2026-07-01 · Period 2026-06-30SEC ↗4Official SEC filingFiled 2026-07-01 · Period 2026-06-30SEC ↗EFFECTOfficial SEC filingFiled 2026-05-29SEC ↗POS AMOfficial SEC filingFiled 2026-05-26SEC ↗3/AOfficial SEC filingFiled 2026-04-20 · Period 2026-03-18SEC ↗4Official SEC filingFiled 2026-04-02 · Period 2026-03-31SEC ↗
EARNINGS / QUARTERLY TRACKER

YD Bio Limited, quarter by quarter.

Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.